Study S002090

A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT05516966
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 64
Start: 2022-10-12
Primary completion: 2023-05-24
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:HRS9531; DRUG:Placebo; DRUG:Dulaglutide Injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Incidence of Adverse Events (Safety and Tolerability) [Screening period up to Day 62]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.